Evotec SE Earnings Recaps
Q3 2025
Nov 6, 2025
Evotec SE reported a 7% decline in year-to-date revenues to EUR 535.1 million, primarily due to ongoing challenges in the early drug discovery market, while its Just-Evotec Biologics division achieved robust growth of 11%.
Key takeaways
- D&PD revenues fell by 12% to EUR 391.9 million, reflecting difficult market conditions amid reduced VC funding in biotech.
- Just-Evotec Biologics reported revenues of EUR 143.2 million, over 100% growth in non-Sandoz and non-DoD business, and a significant deal with Sandoz expected to generate over $650 million.
- Continued focus on cost management with a target of EUR 60 million in cost reductions, exceeding previous expectations, and an additional EUR 50 million in productivity measures planned.
- Momentum in strategic partnerships is strong, with up to 4 molecules anticipated to enter Phase II clinical studies in 2026, enhancing mid-term revenue prospects.
- Proposal activity has increased by 20% over the last two quarters, indicating stabilization in the D&PD business despite prevailing market challenges.
Q2 2025
Aug 13, 2025
Evotec SE reported a 5% decline in total revenues for H1 2025, driven primarily by an 11% drop in the Discovery & Preclinical Development segment, while Just - Evotec Biologics demonstrated strong growth with 16% revenue increase, highlighting the effectiveness of the company's strategic transformation.
Key takeaways
- Total group revenues for H1 2025 reached EUR 371 million, down from H1 2024, with temporary disruptions impacting BMS collaboration.
- Just - Evotec Biologics (JEB) achieved significant growth, solidifying its position as a leader in biologics manufacturing.
- Initiatives to streamline operations and align organizational structure with strategic goals are underway, aimed at enhancing accountability and performance.
- Market conditions remain challenging, particularly in early-stage biotech funding, although signs of recovery are beginning to emerge.
- The planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy of focusing on scalable technology in its biologics segment.